Xerava (Eravacycline Di-Hydrochloride) Patent Expiration, LOE Window & CMS Spending
Xerava (Eravacycline Di-Hydrochloride) by Tetraphase: FDA Orange Book core substance LOE 2037-10-19, 0 AB generics, $961K 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Tetraphase |
| FDA Application & Pathway | N211109 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2037-10-19 |
| Last Listed Patent or Exclusivity Date | 2037-10-19 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $961K |
| 2024 Medicare Part D Spend | $690K |
| 2024 Medicaid Spend | $271K |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 27.9% 2-yr change) |